Toward an effective targeted chemotherapy for multiple myeloma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19509145.
- Also identified by DOI 10.1158/1078-0432.CCR-09-0572.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antibody-drug conjugates (ADCs), cytotoxic drugs chemically linked to antibodies, provide a means to increase the effectiveness of chemotherapy by targeting the drug to neoplastic cells. Anti-CD138 ADCs show promising preclinical efficacy for the treatment of multiple myeloma; however, the safety aspects of targeting CD138 have yet to be explored.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- Immunotoxins
- Multiple Myeloma
- Syndecan-1